NCT01266733

Brief Summary

The purpose of this study is to assess improvement in health related quality of life of fibromyalgia patients following 6 weeks of interdisciplinary treatment compared to the usual treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
153

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Feb 2007

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2007

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2010

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

December 23, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 24, 2010

Completed
Last Updated

June 18, 2015

Status Verified

December 1, 2010

Enrollment Period

2.8 years

First QC Date

December 23, 2010

Last Update Submit

June 17, 2015

Conditions

Keywords

fibromyalgia, non pharmacological intervention

Outcome Measures

Primary Outcomes (1)

  • Health-related quality of life among patients with fibromyalgia (FIQ: Fibromyalgia Impact Questionnaire)

    Fibromyalgia patients completed the FIQ at baseline and again 6 months after the interdisciplinary intervention.

    6 months

Secondary Outcomes (1)

  • Anxiety and depressive symptoms (HADS: The Hospital Anxiety and Depression Scale)

    6 months

Study Arms (2)

Interdisciplinary treatment

EXPERIMENTAL
Behavioral: Interdisciplinary treatmentBehavioral: Interdisciplinary treatment of fibromyalgia

Usual treatment

NO INTERVENTION

Interventions

The Experimental Group received 6 weeks of interdisciplinary treatment of fibromyalgia combining coordinated psychological, medical, educational, and physiotherapeutic interventions delivered by a team that included a physician, a psychologist, and a physiotherapist.Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions. One session included 1 hour with the psychologist and 45 minutes of educational activities with the physician and psychologist, while the other session included 1 hour with the psychologist and 45 minutes with the physiotherapist.

Also known as: Interdisciplinary treatment of fibromyalgia
Interdisciplinary treatment

The Control Group received the usual standard of care, which included pharmacologic treatment with a tricyclic antidepressant (amitriptyline, maximum dose of 75 mg/24h), an analgesic (paracetamol, maximum dose of 4 grams/24h), and a non-opioid central analgesic (tramadol, maximum dose of 400 mg/24h). The Experimental Group (EG) received 6 weeks of interdisciplinary treatment combining coordinated PSYchological, Medical, Educational, and PHYsiotherapeutic interventions (PSYMEPHY) delivered by a team that included a physician, a psychologist, and a physiotherapist. Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions.

Interdisciplinary treatment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • a patient must have been diagnosed with FM according to diagnostic criteria of the American College of Rheumatology
  • being 18 years or older and
  • having had continuous chronic pain for at least 6 months.

You may not qualify if:

  • Patients were excluded if they did not agree to participate in the study,
  • were suffering from a severe psychiatric or organic disorder, or
  • were involved in employment-related legal proceedings related to their FM. Participants in the trial were required to sign an informed consent form.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Galdakao-Usansolo

Galdakao, Bizkaia, 48960, Spain

Location

Related Publications (1)

  • Martin J, Torre F, Padierna A, Aguirre U, Gonzalez N, Matellanes B, Quintana JM. Impact of interdisciplinary treatment on physical and psychosocial parameters in patients with fibromyalgia: results of a randomised trial. Int J Clin Pract. 2014 May;68(5):618-27. doi: 10.1111/ijcp.12365. Epub 2014 Feb 20.

MeSH Terms

Conditions

Fibromyalgia

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System Diseases

Study Officials

  • Fernando Torre, Doctor

    Hospital Galdakao-Usansolo (Bizkaia) Spain

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

December 23, 2010

First Posted

December 24, 2010

Study Start

February 1, 2007

Primary Completion

December 1, 2009

Study Completion

February 1, 2010

Last Updated

June 18, 2015

Record last verified: 2010-12

Locations